3 completed, 1 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Recruiting 1 |
Follow dacomitinib: new trials by email Literature Review of dacomitinib trials Research Report on dacomitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study Afatinib/Dacomitinib, Osimertinib - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Region Skane | 200 | 2022-09-21 | 2026-05-14 |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Dacomitinib (PF-00299804), Gefitinib - Non-small Cell Lung Cancer With EGFR-Activating Mutations | Phase 3 | Completed | Pfizer | 452 | 2013-05-09 | 2023-11-14 |
| ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib - Non-Small Cell Lung Cancer | Phase 3 | Completed | Pfizer | 878 | 2011-06-16 | 2017-05-24 |
| PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer PF-00299804, Placebo - Lung Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 720 | 2009-12-23 | 2023-08-22 |
Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Pfizer (2) · NCIC Clinical Trials Group (1) · Region Skane (1)
South Korea (3) · China (2) · Italy (2) · Japan (2) · Poland (2) · Spain (2) · Sweden (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1)
Michael Millward, MD (1) · Penny Bradbury, MD (1) · Peter Ellis, MD (1)
PMID 26768165, PMID 25439691, PMID 25439692, PMID 26889973, PMID 28958502, PMID 29864379, PMID 31050691, PMID 31313942, PMID 33331989, PMID 33721611, PMID 34120312, PMID 39360943, PMID 42126170